July 2025 Vol 18, No 3

HemOnc.org aims to provide consistently structured, evidence-based, and up-to-date information that is not only clinically relevant but also immediately usable to everyone, including pharmacists, other healthcare providers, and patients.

The use of circulating tumor DNA is emerging as a powerful tool in colorectal cancer management, but its potential to address disparities in care remains an ongoing challenge.

The phase 3 S2302 Pragmatica-Lung study offers a new blueprint for cancer clinical trials, one that emphasizes simplification, inclusivity, and real-world applicability, according to Konstantin Dragnev, MD, of Dartmouth Cancer Center.

Nurses and navigators, especially those embedded in community programs, can help bridge the access gap by promoting education, building trust, and facilitating access early in the patient journey.

Advances in technology, including artificial intelligence and telemedicine platforms, offer promising avenues to support precision oncology efforts remotely.

Despite their therapeutic potential, the adoption and utilization of bispecific antibodies exhibit significant disparities, particularly between urban and rural healthcare settings.